Compare MKSI & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKSI | UTHR |
|---|---|---|
| Founded | 1961 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9B | 25.1B |
| IPO Year | 1997 | 1999 |
| Metric | MKSI | UTHR |
|---|---|---|
| Price | $371.65 | $551.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 14 |
| Target Price | $263.31 | ★ $567.57 |
| AVG Volume (30 Days) | ★ 943.6K | 401.3K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | ★ 55.52 | 13.07 |
| EPS | 1.18 | ★ 5.82 |
| Revenue | ★ $3,931,000,000.00 | $1,483,300,000.00 |
| Revenue This Year | $15.87 | $6.39 |
| Revenue Next Year | $10.87 | $14.18 |
| P/E Ratio | $310.74 | ★ $94.32 |
| Revenue Growth | ★ 9.62 | 2.38 |
| 52 Week Low | $88.49 | $272.18 |
| 52 Week High | $379.99 | $609.35 |
| Indicator | MKSI | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 67.84 | 47.30 |
| Support Level | $131.70 | $464.92 |
| Resistance Level | N/A | $557.97 |
| Average True Range (ATR) | 16.84 | 12.30 |
| MACD | 4.11 | 0.20 |
| Stochastic Oscillator | 85.93 | 59.89 |
MKS Inc delivers foundational technology solutions for leading edge semiconductor manufacturing, electronics and packaging, and specialty industrial applications. The company provides instruments, components, subsystems, systems, process control solutions, and specialty chemicals technology that improve process performance and optimize productivity. Its solutions address challenges of miniaturization and complexity in device manufacturing, enabling increased power, speed, and feature enhancement. MKS Inc operates through three divisions: Vacuum Solutions Division (VSD), Photonics Solutions Division (PSD), and Materials Solutions Division (MSD). The company operates in the United States, which generates maximum revenue, as well as China and other countries.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.